Dr. Frank C. Cackowski, MD
Medical Oncology (Medical Oncology Physician)
1500 E Medical Center Dr., B1 Floor Cancer Recp D
Ann Arbor, MI 48109
- Medicare participating
At a glance
- Medical school
- University of Pittsburgh School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 82
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Pittsburgh School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MI license 4301098306 -
Hematology & Oncology Physician
MI license 4301098306 -
Internal Medicine Physician
MI license 4301098306
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Harper University Hospital Detroit, MI
- Karmanos Cancer Center Detroit, MI
Medical groups
- University Physician Group (403 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 82
- Services billed
- 241
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 156 | 62 |
| Established patient office or other outpatient visit, 20-29 minutes | 61 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
| Established patient office or other outpatient visit, 40-54 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Ann Arbor, MI | 70 |
| Abiraterone Acetate | 68 |
| Xtandi (enzalutamide) | 52 |
| Orgovyx (relugolix) | 19 |
| Nubeqa (darolutamide) | 15 |
| Dexamethasone Other prescribers in Ann Arbor, MI | 14 |
| Amlodipine Besylate Other prescribers in Ann Arbor, MI | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $1,379,247 in research payments for these studies, mostly to the institutions running them.
- A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic …
AstraZeneca UK Limited - BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical
Bayer HealthCare Pharmaceuticals Inc. - BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned
Bayer HealthCare Pharmaceuticals Inc. - A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Pa…
Novartis Pharmaceuticals Corporation - BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy …
Bayer HealthCare Pharmaceuticals Inc. - Pylarify pet-ct or pet-mri in men with favorable intermediate risk -fir- prostate cancer -mirror
Progenics Pharmaceuticals, Inc. - Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Eli Lilly and Company - A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06926868
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.